TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease — Stella

Recruiting

Back to Crohn Disease trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

South Korea

Asan Medical Center, Seoul

Key details

Phase

Post-approval study

Sponsor

Asan Medical Center

Enrollment target

~86 participants

Started

November 2023

Primary completion

June 2026

Age range

19 Years – 80 Years

Last updated May 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov